{
  "docId": "019de075-4aec-72cf-a6e0-519f4b0af11c",
  "docSlug": "80e6ab6db3df4d91b63f99a2a4cf6dc3",
  "documentTitle": "Exscientia | Investor Presentation Deck | 73 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 73,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a three-column layout to define the target product profile (TPP) requirements for a CDK7 inhibitor.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4aec-72cf-a6e0-519f4b0af11c/39",
  "deckHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c",
  "deckJsonHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c.json",
  "deckAnchorHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.68,
        "y": 0.72
      },
      "kind": "callout",
      "text": "Goal is for very rapid absorption at the lowest possible dose",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "112a7689-657c-4e3e-9523-d42ccf4b8f7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.07,
        "y": 0.72
      },
      "kind": "callout",
      "text": "Design needs to achieve potency and selectivity non-covalently",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47a0d8f0-1301-4345-b125-74c51ac6c706",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.38,
        "y": 0.72
      },
      "kind": "callout",
      "text": "Product needs to be highly potent, but with a short half-life",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a22917a9-d338-4aa9-a4cc-9bf430db614d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.38,
        "y": 0.28
      },
      "kind": "list",
      "text": "Short Therapeutic Window: Ideal therapeutic coverage would be 6-8 hours at IC80; Longer periods would lead to increasing systemic toxicity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "527aa277-d537-42d3-97c1-129a08366bee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.07,
        "y": 0.28
      },
      "kind": "list",
      "text": "Non-covalent Potency and Selectivity: Both potency and selectivity are critically important; Early entrants increased potency and selectivity by covalent bonding; This dramatically increased off target toxicity, leading to discontinuation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e09d724c-2937-42b5-a37c-60381f300a88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.68,
        "y": 0.28
      },
      "kind": "list",
      "text": "Bioavailable: CDK7 inhibition will lead to toxicity if it remains at any site other than the tumour; Absorption variability will cause either supra-doses or sub-therapeutic dosing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f06e103a-43ab-4659-936b-1206a30e793e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.07,
        "y": 0.14
      },
      "kind": "title",
      "text": "Mechanism requires a tightly controlled target product profile",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5e62415-fc3c-417d-9381-ac86339b96a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Precision design to maximise effectiveness",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d2e49e5-e0d4-407b-8835-9db55c1edfe3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Design principle",
      "slug": "design-principle",
      "agent": null,
      "layer": "slide",
      "matchId": "68c5c07a-d8ec-49b0-9e93-54db02bd44f6",
      "evidence": "Non-covalent Potency and Selectivity: Both potency and selectivity are critically important",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "target-product-profile",
      "slug": null,
      "matchId": "df6313b3-3226-4aa6-b1a0-4ac789870516",
      "evidence": "The slide explicitly defines the requirements for a drug candidate's profile.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 73,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "02ebf716-8af1-4eca-8937-1321b5d2471c",
      "evidence": "The deck presents the consequences of not adopting Exscientia's technology throughout the presentation",
      "position": 0,
      "objective": "What is the cost of not adopting Exscientia's AI-driven precision medicine platform?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 72,
      "from": 29,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "c1ff2e13-046f-4a68-9f90-d544bd3e6de9",
      "evidence": "The deck presents information on Exscientia's clinical stage compounds and their potential benefits",
      "position": 1,
      "objective": "What are the potential benefits of Exscientia's clinical stage compounds?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}